NYSE:ABBV - AbbVie Stock Price, Forecast & News

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

AbbVie declared a -- dividend on Friday, November 1st. Shareholders of record on Wednesday, January 15th will be given a dividend of $1.18 per share on Friday, February 14th. This represents a yield of 5.93%. The ex-dividend date is Tuesday, January 14th. This is a positive change from AbbVie's previous -- dividend of $1.07. View AbbVie's Dividend History.

AbbVie announced that its Board of Directors has initiated a share repurchase program on Thursday, December 13th 2018, which permits the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to reacquire up to 3.8% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company's management believes its stock is undervalued.

AbbVie Inc (NYSE:ABBV) posted its quarterly earnings results on Friday, November, 1st. The company reported $2.33 earnings per share for the quarter, beating the consensus estimate of $2.29 by $0.04. The firm had revenue of $8.48 billion for the quarter, compared to analysts' expectations of $8.37 billion. AbbVie had a negative return on equity of 155.96% and a net margin of 9.90%. The business's revenue was up 3.0% compared to the same quarter last year. During the same period in the previous year, the company posted $2.14 EPS. View AbbVie's Earnings History.

AbbVie is scheduled to release their next quarterly earnings announcement on Friday, February 7th 2020. View Earnings Estimates for AbbVie.

AbbVie will be holding an earnings conference call on Friday, February 7th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

AbbVie issued an update on its FY19 earnings guidance on Friday, November, 1st. The company provided EPS guidance of $8.90-8.92 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.90.

13 equities research analysts have issued 12 month target prices for AbbVie's shares. Their forecasts range from $66.61 to $98.00. On average, they expect AbbVie's stock price to reach $86.33 in the next twelve months. This suggests a possible upside of 3.3% from the stock's current price. View Analyst Price Targets for AbbVie.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 1 sell rating, 6 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AbbVie.

Media stories about ABBV stock have trended extremely negative recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AbbVie earned a daily sentiment score of -4.5 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for AbbVie.

Some companies that are related to AbbVie include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Horizon Therapeutics (HZNP), The Medicines (MDCO), Nektar Therapeutics (NKTR), Zogenix (ZGNX) and Pacira Biosciences (PCRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), Wheaton Precious Metals (WPM), Rogers Communications (RCI), Open Text (OTEX), Valeant Pharmaceuticals Intl (VRX) and AT&T (T).

AbbVie's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include New York State Teachers Retirement System (0.15%), Artemis Investment Management LLP (0.07%), Hamlin Capital Management LLC (0.06%), Strs Ohio (0.06%), State of Michigan Retirement System (0.06%) and Candriam Luxembourg S.C.A. (0.05%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.

ABBV stock was sold by a variety of institutional investors in the last quarter, including Galibier Capital Management Ltd., Ambassador Advisors LLC, Candriam Luxembourg S.C.A., Commerzbank Aktiengesellschaft FI, Meag Munich Ergo Kapitalanlagegesellschaft MBH, OLD National Bancorp IN, Strs Ohio and TIAA FSB. Company insiders that have sold AbbVie company stock in the last year include Azita Saleki-Gerhardt, Brian L Durkin, Laura J Schumacher and Timothy J Richmond. View Insider Buying and Selling for AbbVie.

ABBV stock was bought by a variety of institutional investors in the last quarter, including Johanson Financial Advisors Inc., Zurcher Kantonalbank Zurich Cantonalbank, Artemis Investment Management LLP, CHURCHILL MANAGEMENT Corp, State of Michigan Retirement System, 6 Meridian, First American Bank and Rhenman & Partners Asset Management AB. Company insiders that have bought AbbVie stock in the last two years include Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Roxanne S Austin and William J Chase. View Insider Buying and Selling for AbbVie.

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ABBV stock can currently be purchased for approximately $83.54.

AbbVie has a market capitalization of $123.54 billion and generates $32.75 billion in revenue each year. The company earns $5.69 billion in net income (profit) each year or $7.91 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.View Additional Information About AbbVie.

The official website for AbbVie is http://www.abbvie.com/.

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.